Get started
Author

Wenjuan Wu

Observed names: W Wu, WEN-JUAN WU, Wen-Juan Wu
Observed institutions: The University of Texas MD Anderson Cancer Center, Eli Lilly (United States), Hebei North University, Bengbu Medical College, Third Hospital of Hebei Medical University, First Hospital of Lanzhou University
ORCID: 0000-0002-0742-8160
Observed ORCID: 0000-0002-0742-8160
OpenAlex ID: A5102751895
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models
2012 · S. Betty Yan, Victoria L. Peek, et al. · Investigational New Drugs · 177
PDF
ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine
2019 · Shripad V. Bhagwat, William T. McMillen, et al. · Molecular Cancer Therapeutics · 114
RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1
2017 · S-H Chen, X Gong, et al. · Oncogene · 74
Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET
2013 · Wenjuan Wu, Chen Bi, et al. · Clinical Cancer Research · 67
Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
2017 · Genshi Zhao, Colin F. Green, et al. · Molecular Cancer Therapeutics · 48
Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor
2021 · David S. Hong, Kathleen N. Moore, et al. · Clinical Cancer Research · 47
PDF
Expression of epidermal growth factor (EGF)/transforming growth factor-α by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice
2007 · Wenjuan Wu, Michael S. O'Reilly, et al. · Molecular Cancer Therapeutics · 41
Activation of ALDH2 with Low Concentration of Ethanol Attenuates Myocardial Ischemia/Reperfusion Injury in Diabetes Rat Model
2016 · Pin-Fang Kang, Wen-Juan Wu, et al. · Oxidative Medicine and Cellular Longevity · 36
PDF
A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib
2020 · Wayne D. Blosser, Jack A. Dempsey, et al. · Oncotarget · 28
PDF
Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma
2020 · Ritu Chaudhary, Robbert J. C. Slebos, et al. · Molecular Carcinogenesis · 27
Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells
2020 · Lacey M. Litchfield, Karsten Boehnke, et al. · Oncotarget · 27
Changes in cardiac mitochondrial aldehyde dehydrogenase 2 activity in relation to oxidative stress and inflammatory injury in diabetic rats
2013 · HONG-JU WANG, PIN-FANG KANG, et al. · Molecular Medicine Reports · 26
PDF
Progress of medicinal plants and their active metabolites in ischemia-reperfusion injury of stroke: a novel therapeutic strategy based on regulation of crosstalk between mitophagy and ferroptosis
2024 · Guozhen Zhang, Qiang Wang, et al. · Frontiers in Pharmacology · 22
PDF
Abstract 4973: Discovery of LY3214996, a selective and novel ERK1/2 inhibitor with potent antitumor activities in cancer models with MAPK pathway alterations
2017 · Shripad V. Bhagwat, William T. McMillen, et al. · Cancer Research · 22
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Does Not Improve Paclitaxel Effect in an Orthotopic Mouse Model of Lung Cancer
2004 · Amir Onn, Takeshi Isobe, et al. · Clinical Cancer Research · 20
Construction of a Novel Constitutively Active Chimeric EGFR to Identify New Targets for Therapy
2005 · Hua Cheng, Robert R. Langley, et al. · Neoplasia · 14
PDF
Abstract 1776: Antitumor activity of Chk1 inhibitor LY2606368 as a single agent in SW1990 human pancreas orthotopic tumor model
2012 · Wenjuan Wu, Chen Bi, et al. · Cancer Research · 8
In Vivo Pre-Clinical Evaluation of LOXO-305 Alone and in Combination with Venetoclax, Rituximab, R-CHOP or Obinutuzumab on Human Xenograft Lymphoma Tumor Models in Mice
2020 · Eliana B. Gomez, Wenjuan Wu, et al. · Blood · 6
Abstract 336: Anti-tumor activity of the Chk1 inhibitor prexasertib (LY2606368) as a single agent in triple negative breast cancer models
2018 · Wenjuan Wu, Constance King, et al. · Cancer Research · 4
Abstract 3508: Combination of the Chk1 inhibitor (prexasertib) with a PI3K/mTOR inhibitor (LY3023414) induces synergistic anti-tumor activity in triple negative breast cancer (TNBC) models
2019 · Wenjuan Wu, Greg Donoho, et al. · Cancer Research · 3
Abstract 1761: Inhibition of PI3K/AKT/mTOR signaling by a dual PI3K/mTOR inhibitor (LY3023414) potentiates the antitumor efficacy of the Chk1 inhibitor prexasertib (LY2606368) in models of human high-grade serous ovarian cancer (HGSOC)
2019 · Jack Dempsey, Greg Donoho, et al. · Cancer Research · 3
Abstract 2586: PI3K/AKT signaling pathway is transcriptionally elevated in prexasertib-resistant TNBC PDX models
2018 · Yan Ding, Jiangang Liu, et al. · Cancer Research · 3
Mellissa officinalis Leaf Aqueous Extract Green-Formulated Nanoparticles as a new Chemotherapeutic Drug in the Field of Healthcare and Nursing: Determination of Anti-Cancer, Antioxidant, and Cytotoxicity Effects
2024 · Shan Fang, Yuan Li, et al. · Science of Advanced Materials · 2
Effects of angiopoietin (Ang) 1/endothelial-enriched Tunica interna endothelial cell kinase 2 (Tie2) signaling pathway on autophagy-based neuroprotection and expression of aquaporin 4
2024 · Wenjuan Wu, Xiaojuan Liu, et al. · Materials Express · 1
Effects of prexasertib, a CHK1 inhibitor, in the immune microenvironment of head and neck squamous cell carcinoma (HNSCC).
2020 · Ritu Chaudhary, Robbert Slebos, et al. · Journal of Clinical Oncology · 1
Works count: 53
Citation count: 825
H-index: 15
I10-index: 16
Year
Topic
Type